and the process for developing the agenda; (3) Three working groups including researchers, health professionals, and representatives of stakeholder organizations will meet before the Regional meetings are convened to provide individual input and recommendations based on the communities they represent; (4) A final public meeting will be held on March 1, 1996, in Washington, DC, to present a preliminary research agenda and receive public comment. The public is encouraged to provide oral comments at the public meetings and written comments as soon as possible. Written comments may be submitted until the close of business, March 6, 1996.

The final agenda will be presented at a scientific symposium commemorating the 25th anniversary of the Occupational Safety and Health Act on April 29, 1996.

NIOSH encourages the public to provide recommendations on research priorities, criteria for determining priorities, and the process of developing the research agenda. To receive more information, contact Ms. Kathy Sykes through the NIOSH toll-free information service. On-site registration will be available; however, to assist in planing for the meeting, advance registration is requested. To register in advance to attend and to speak at the Regional meetings, please contact Ms. Diane Manning. If registering in writing, please provide your name, address, phone and fax number, and indicate if you wish to make a presentation.

Addresses: Written public comments on the National Occupational Research Agenda should be mailed to Ms. Diane Manning, NIOSH, CDC, Robert A. Taft Laboratories, M/S C34, 4676 Columbia Parkway, Cincinnati, Ohio 45226, telephone 513/533–8450, FAX 513/533–8285.

Contact Person for Additional Information: Ms. Kathy Sykes, NIOSH, CDC, 200 Independence Avenue, Room 317B, Washington, DC 20201, telephone NIOSH toll-free number 800/356–4674, or 202/401–3747, FAX 202/260–1898.

Dated: January 24, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–1828 Filed 1–30–96; 8:45 am]

BILLING CODE 4163–19–M

Food and Drug Administration

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice–mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5–digit number. This 5–digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5–digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

Medical Imaging Drugs Advisory Committee

Date, time, and place. February 15, 1996, 8:30 a.m., Holiday Inn—Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Type of meeting and contact person. Open public hearing, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 5 p.m.; Leander B. Madoo, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4695, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Medical Imaging Drugs Advisory Committee, code 12540.

General function of the committee. The committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before February 9, 1996, and submit a brief statement of the general nature of the evidence or the arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss and begin drafting ''Points to Consider (PTC) for Developing Medical Imaging Agents.'' The purpose of the meeting is to provide the committee opportunity to work together on this draft and not primarily to hear presentations. The agents encompassed will include radiologic contrast media and nuclear medicine pharmaceuticals. Written comments will be accepted until April 15, 1996, and will be available in the Dockets Management Branch for public inspection under docket number 95N–0414 (Dockets Management Branch, HFA–305, Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857).

Medical Imaging Drugs Advisory Committee

Date, time, and place. February 16, 1996, 8:30 a.m., Holiday Inn—Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Type of meeting and contact person. Open public hearing, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 3 p.m.; Leander B. Madoo, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4695, or William Freas, Center for Biologics Evaluation and Research (HFM–21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Medical Imaging Drugs Advisory Committee, code 12540.

General function of the committee. The committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before February 9, 1996, and submit a brief statement of the general nature of the evidence or the arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss product license application (PLA) 91–0209, from Immunomedics, for Immu–4, a murine monoclonal antibody fragment directed against the carcinoembryonic antigen (CEA).

Gastrointestinal Drugs Advisory Committee

Date, time, and place. February 22 and 23, 1996, 9 a.m., Washingtonian Center Marriott, 9752 Washington Blvd., Gaithersburg, MD.

Type of meeting and contact person. Open public hearing, February 22, 1996, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 4:30 p.m.; open committee discussion, February 23, 1996, 9 a.m. to 4:30 p.m.; Joan C. Standaert (HFD–180), 419–259–6211, or Valerie M. Mealy (HFD–21), 301–443–4695, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Gastrointestinal Drugs Advisory Committee, code 12538.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in gastrointestinal diseases.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before February 13, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. On February 22, 1996, the committee will discuss new drug application (NDA) 20–580, Cotazyme, and NDA 20–581, Cotazyme S and Zymase (pancreatic lipase, Organon), indicated for exocrine pancreatic insufficiency. On February 23, 1996, the committee will discuss NDA 20–617, C–14 Urea Breath Test (Trimed Specialties Inc.), for diagnosis of *Helicobacter pylori* .

Biological Response Modifiers Advisory Committee

Date, time, and place. February 28 and 29, 1996, 8:30 a.m., Holiday Inn—Bethesda, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Type of meeting and contact person. Open public hearing, February 28, 1996, 8:30 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 5 p.m.; open public hearing, February 29, 1996, 8:30 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 2 p.m.; William Freas or Pearline Muckelvene, Center for Biologics Evaluation and Research (HFM–21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Biological Response Modifiers Advisory Committee, code 12388.

General function of the committee. The committee reviews and evaluates data relating to the safety, effectiveness, and appropriate use of biological response modifiers which are intended for use in the prevention and treatment of a broad spectrum of human diseases.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before February 12, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. On February 28, 1996, the committee will: (1) Discuss premarket approval application (PMA) 94–001, for CEPRATE SC Device (CellPro), for selection of CD34+ progenitor/stem cells, and (2) then receive an update on stem cell policy. On February 29, 1996, the committee will discuss: (1) Clinical trials in in utero stem cell transplantation: Issues in early clinical trial development, and (2) the draft document ''Addendum on Gene Therapy to the 1991 Points to Consider (PTC) on Human Somatic Cell and Gene Therapy.'' The draft document will be available at the meeting and is also available through the CBER FAX Information System at 301–594–1939 from a touch tone phone.

Antiviral Drugs Advisory Committee

Date, time, and place. February 28 and 29, and March 1, 1996. February 28 and 29, 1996, 8:30 a.m., Holiday Inn—Gaithersburg, Grand Ballroom, Two Montgomery Village Ave., Gaithersburg, MD; March 1, 1996, 8:30 a.m., Holiday Inn—Silver Spring, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Type of meeting and contact person. Open committee discussion, February 28, 1996, 8:30 a.m. to 1 p.m.; open public hearing, 1 p.m. to 2 p.m., unless public participation does not last that long; open committee discussion, 2 p.m. to 5 p.m.; open committee discussion, February 29, 1996, 8:30 a.m. to 11 a.m.; open public hearing, 11 a.m. to 12 m., unless public participation does not last that long; open committee discussion, 12 m. to 5 p.m.; open committee discussion, March 1, 1996, 8:30 a.m. to 11 a.m.; open public hearing, 11 a.m. to 12 m., unless public participation does not last that long; open committee discussion, 12 m. to 5 p.m.; Ermona B. McGoodwin or Liz Ortuzar, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Antiviral Drugs Advisory Committee, code 12531.

General function of the committee. The committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of acquired immune deficiency syndrome (AIDS), AIDS-related complex (ARC), and other viral, fungal, and mycobacterial infections.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before February 23, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. On February 28, 1996, the committee will discuss recent studies with nucleoside analogues for the treatment of human immunodeficiency virus (HIV) infection. The discussion will include data from AIDS Clinical Trial Group (ACTG) Study 175, the Delta studies, and other relevant studies. Data pertinent to the following NDA's will be included in the discussion: Bristol Myers Squibb NDA's 20–154, 20–155, and 20–156 for Videx® (didanosine) chewable tablets, buffered powder for oral solution, and pediatric powder for

oral solution; Glaxo Wellcome NDA's 19–665 and 19–910 for Retrovir® (zidovudine) capsules and syrup; Roche Laboratories' NDA 20–199 for HIVID® (zalcitabine) tablets. On February 29, 1996, the committee will discuss data relevant to NDA's 20–659 and 20–680 ritonavir (liquid and capsules, Abbott Laboratories) for treatment of HIV infection. On March 1, 1996, the committee will discuss data relevant to NDA 20–685 Crixivan™ (indinavir capsules, Merck and Co., Inc.) for treatment of HIV infection.

Endocrinologic and Metabolic Drugs Advisory Committee

Date, time, and place. February 29, 1996, 8 a.m., Holiday Inn—Gaithersburg, Goshen Room, Two Montgomery Village Ave., Gaithersburg, MD.

Type of meeting and contact person. Open public hearing, 8 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 5 p.m.; Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, FAX: 301–443–0699, or FDA Advisory Committee Information Hotline, 1– 800–741–8138 (301–443–0572 in the Washington, DC area), Endocrinologic and Metabolic Drugs Advisory Committee, code 12536.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in endocrine and metabolic disorders.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before February 21, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will hear presentations and discuss data submitted regarding the safety and efficacy of NDA 20–563, Humalog® , (insulin lispro [rDNA origin], Eli Lilly) for treatment of insulin dependent diabetes mellitis.

Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Antiviral Drugs Advisory Committee

Date, time, and place. March 1, 1996, 8 a.m., Holiday Inn—Gaithersburg, Grand Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Type of meeting and contact person. Open committee discussion, 8 a.m. to 1 p.m.; open public hearing, 1 p.m. to 2 p.m., unless public participation does not last that long; open committee discussion, 2 p.m. to 5 p.m.; Kathleen R. Reedy, Ermona McGoodwin, or Angie Whitacre, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, FAX: 301–443–0699, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Endocrinologic and Metabolic Drugs Advisory Committee, code 12536.

General functions of the committees. The Endocrinologic and Metabolic Drugs Advisory Committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in endocrine and metabolic disorders. The Antiviral Drugs Advisory Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of acquired immune deficiency syndrome (AIDS), AIDS-related complex (ARC), and other viral, fungal, and mycobacterial infections.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before February 21, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will hear presentations and discuss data submitted regarding the safety and efficacy of NDA 20–604, Serostim®, (somatropin [rDNA], Serono Laboratories, Inc.) for treatment of AIDS-wasting associated with catabolism, weight loss or cachexia.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this Federal Register notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page.

The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: January 26, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–2045 Filed 1–30–96; 8:45 am]

BILLING CODE 4160–01–F

Health Resources and Services Administration

Advisory Council; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), announcement is made of the following National Advisory bodies scheduled to meet during the month of February 1996:

Name: National Advisory Council on Migrant Health

Date and Time: February 23–24, 1996—8:00 a.m.

Place: East West Towers, 9th Floor, Conference Room A, 4350 East West Highway, Bethesda, Maryland 20814, 914/631–2200

The meeting is open to the public.

Agenda: This will be a meeting of the Executive Committee. The agenda includes a overview of Council general business activities and priorities. A special emphasis will be given to the issue of workers compensation. In addition, the Executive Committee will review and discuss the 1996 National Advisory Council on Migrant Health Recommendations with federal representatives.

The Council meeting is being held in conjunction with the National Association of Community Health Centers, Policy and Issues Forum, February 23–27, 1996.

Anyone requiring information regarding the subject Council should contact Susan Hagler, Migrant Health Program, Staff Support to the National Advisory Council on Migrant Health, Bureau of Primary Care, Health Resources and Services Administration, 4350 East West Highway, Room 7–A51, Rockville, Maryland 20857, Telephone (301) 594–4302.

Name: Advisory Commission on Childhood Vaccines (ACCV)

Date and Time: February 28–29, 9:00 am–5:00 pm

Place: Parklawn Building, Conference Room D, 5600 Fishers Lane, Rockville, Maryland 20857

The meeting is open to the public.

The first day of the meeting, February 28, from 9:00 a.m–12:00 noon, will consist of a meeting of the Commission's working Subcommittees: ACCV Subcommittee on Vaccine Safety (meeting jointly with the National Vaccine Advisory Committee Subcommittee on Vaccine Safety)

Agenda: Agenda items will include, but not be limited to: a review of the report of the Task Force on Safer Childhood Vaccines and prioritization of its recommendations.

The full Commission will meet on the afternoon of February 28 from 1:00 p.m. to 5:00 p.m., and February 29 from 9:00 a.m to 12:00 noon. Agenda items will include, but not be limited to: orientation of new members; a review of vaccine information statements; a vaccine safety update from the Centers for Disease Control and Prevention and the Food and Drug Administration; and routine Program reports.

Public comment will be permitted before the Subcommittee adjourns on February 28; and before the end of the full Commission meeting on February 28 and 29. Oral presentations will be limited to 5 minutes per public speaker. Persons interested in providing an oral presentation should submit a written request, along with a copy of their presentation to Mr. Jerry Anderson, Principal Staff Liaison, Division of Vaccine Injury Compensation, Bureau of Health Professions, Health Resources and Services Administration, Room 8A–35, 5600 Fishers Lane, Rockville, MD 20852; Telephone (301) 443–1533.

Requests should contain the name, address, telephone number, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative. The allocation of time may be adjusted to accommodate the level of expressed interest. The Division of Vaccine Injury Compensation will notify each presenter by mail or telephone of their assigned presentation time. Persons who do not file an advance request for presentation, but desire to make an oral statement, may sign up in Conference Room D on February 28 and 29. These persons will be allocated time as time permits.

Anyone requiring information regarding the Commission should contact Mr. Anderson, Division of Vaccine Injury Compensation, Bureau of Health Professions, Health Resources and Services Administration, Room 8A–35, 5600 Fishers Lane, Rockville, Maryland 20852; Telephone (301) 443–1533.

Agenda Items are subject to change as priorities dictate.

Dated: January 24, 1996.

Jackie E. Baum,

Advisory Committee Management Officer, HRSA.

[FR Doc. 96–1665 Filed 1–30–96; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Community Planning and Development

[Docket No. FR–3873–N–02]

Continuum of Care Homeless Competition, Supportive Housing Program, Shelter + Care Program, Single Room Occupancy Program

Announcement of Funding Awards—Fiscal Year 1995

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice.

SUMMARY: In accordance with section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989, this notice announces the funding decisions made by the Department in a competition for funding under the Fiscal Year 1995 Continuum of Care Competition (Supportive Housing Program, Shelter + Care Program and Single Room Occupancy Program). The notice contains the names of award winners and the amounts of the awards.

FOR FURTHER INFORMATION CONTACT: Maggie Taylor, Director, Office of Special Needs Assistance Programs, Department of Housing and Urban Development, Room 7262, 451 Seventh Street, SW, Washington, DC 20410, telephone (202) 708–4300. The TDD number for the hearing impaired is (202) 708–2565. (These are not toll-free numbers).

SUPPLEMENTARY INFORMATION. The purpose of the competition was to award grants for the development of continuum of care systems through supportive housing and supportive services, rental assistance, and services including innovative approaches to assist homeless persons in the transition from homelessness and to enable them to live as independently as possible.

The assistance made available in this announcement is authorized by the Stewart B. McKinney Homeless Assistance Act of 1987, as amended. The competition was announced in a Notice of Funding Availability (NOFA) published in the Federal Register on February 17, 1995 (60 FR 9534). Applications were rated and selected for funding on the basis of selection criteria contained in that Notice.

A total of $902,585,052 was awarded for 485 applications in 228 communities. In accordance with